Phase 3 N=523 Randomized Health Services Research

PreHospital Air Medical Plasma Trial

Hemmorhagic Shock During Air Medical Transport

Bottom Line

View on ClinicalTrials.gov: NCT01818427 ↗

Enrolled (actual)

523

Serious AEs

0.6%

Results posted

Oct 2018

Primary outcome: Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: infusion of 2 units of plasma (Biological)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Jason Sperry
Primary completion: Sep 2017

Outcome Measures

Outcome	Result	p-value
PRIMARY Our Primary Outcome for the Proposal Will be 30 Day Mortality	53; 89	—
SECONDARY Twenty Four-Hour Blood Transfusion Requirements	3; 4	—
SECONDARY In-hospital Mortality	51; 88	—
SECONDARY Multiple Organ Failure	145; 156	—
SECONDARY Acute Lung Injury (ALI) and Transfusion Related Acute Lung Injury (TRALI)	48; 50	—

Summary

To determine the effect of the prehospital infusion during air transport of 2 units of AB plasma on 30 day mortality in patients with hemorrhagic shock as compared to conventional care.

Eligibility Criteria

Inclusion Criteria: Hemorrhagic shock not responsive to crystalloid infusion - Exclusion Criteria: Isolated Fall, Cervical cord injury, prisoner, pregnant patient, traumatic arrest -

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01818427). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.